About
Spikimm develops human monoclonal antibody therapies to prevent severe viral infections, focusing on BK virus reactivation in immunocompromised patients such as kidney transplant recipients.
Explore Spikimm's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.